The catastrophic phase 1 clinical trial of German biotech TeGenero's monoclonal antibody designed to activate the immune system's T cells has raised serious concerns about the adequacy of the preclinical tests routinely used during the development of novel biologic drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Sheridan, C. TeGenero fiasco prompts regulatory rethink. Nat Biotechnol 24, 475–476 (2006). https://doi.org/10.1038/nbt0506-475
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0506-475
This article is cited by
-
Twitter storm forces Chimerix's hand in compassionate use request
Nature Biotechnology (2014)
-
Industry pursues co-stimulatory receptor immunomodulators to treat cancer
Nature Biotechnology (2013)
-
Immunostimulatory monoclonal antibodies for cancer therapy
Nature Reviews Cancer (2007)
-
Critics pan timid European response to TeGenero disaster
Nature Biotechnology (2007)
-
The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery
Nature Reviews Immunology (2007)